|
Variables
|
Training cohort (n = 381)
|
Validation cohort (n = 163)
|
P
|
|---|
|
Age, years
|
51.3 ± 11.2
|
50.2 ± 11.5
|
0.301
|
|
Sex
| | |
0.410
|
|
Male
|
324 (85.0%)
|
143 (87.7%)
| |
|
Female
|
57 (15.0%)
|
20 (12.3%)
| |
|
BMI, Kg/m2
| | |
0.713
|
|
< 18.5
|
27 (7.1%)
|
12 (7.4%)
| |
|
18.5–25
|
258 (67.7%)
|
116 (71.2%)
| |
|
≥ 25
|
96 (25.2%)
|
35 (21.5%)
| |
|
HBsAg
| | |
0.327
|
|
Positive
|
328 (86.1%)
|
135 (82.8%)
| |
|
Negative
|
53 (13.9%)
|
28 (17.2%)
| |
|
HBV-DNA (copies/ml)
| | | |
|
< 103
|
176 (46.2%)
|
79 (48.5%)
|
0.645
|
|
≥ 103
|
205 (53.8%)
|
84 (51.5%)
| |
|
Liver cirrhosis
| | |
0.142
|
|
Present
|
263 (69.0%)
|
102 (62.6%)
| |
|
Absent
|
118 (31.0%)
|
61 (37.4%)
| |
|
Child-Pugh classification
| | |
0.204
|
|
A
|
367 (96.3%)
|
161 (98.8%)
| |
|
B
|
14 (3.7%)
|
2 (1.2%)
| |
|
Previous abdominal surgery
| | |
0.705
|
|
Present
|
61 (16.0%)
|
24 (14.7%)
| |
|
Absent
|
320 (84.0%)
|
139 (85.3%)
| |
|
Comorbidities
| | |
0.012
|
|
Present
|
73 (19.2%)
|
17 (10.4%)
| |
|
Absent
|
308 (80.8%)
|
146 (89.6%)
| |
|
AFP, ng/mL
| | |
0.091
|
|
< 400
|
233 (61.2%)
|
87 (53.4%)
| |
|
≥ 400
|
148 (38.8%)
|
76 (46.6%)
| |
|
CEA, ng/mL
| | |
0.575
|
|
Normal
|
297 (78.0%)
|
131 (80.4%)
| |
|
Abnormal
|
84 (22.0%)
|
32 (19.6%)
| |
|
CA19–9, U/ml
| | |
0.588
|
|
Normal
|
233 (61.2%)
|
104 (63.8%)
| |
|
Abnormal
|
148 (38.8%)
|
59 (36.2%)
| |
|
TBIL, umol/L
|
14.0 (10.9–17.8)
|
13.7 (11.0–18.4)
|
0.794
|
|
DBIL, umol/L
|
5.4 (4.1–6.8)
|
5.3 (4.2–6.8)
|
0.853
|
|
ALT, IU/L
|
38.0 (27.0–56.8)
|
39.0 (25.0–62.0)
|
0.974
|
|
AST, IU/L
|
38.0 (30.0–58.0)
|
39.0 (30.0–59.0)
|
0.875
|
|
Albumin, g/L
| | |
0.909
|
|
<35
|
27 (7.1%)
|
12 (7.4%)
| |
|
≥ 35
|
354 (92.9%)
|
151 (92.6%)
| |
|
NLR
|
2.2 (1.7–3.1)
|
2.3 (1.6–3.2)
|
0.776
|
|
PLR
|
92.9 (65.1–128.3)
|
84.7 (64.0–135.9)
|
0.
|
|
ASA grade
| | |
0.088
|
|
II
|
316 (82.9%)
|
125 (76.7%)
| |
|
III
|
65 (17.1%)
|
38 (23.3%)
| |
|
Largest tumor size, cm
|
5.0 (3.2–7.8)
|
5.6 (3.4–9.0)
|
0.106
|
|
Tumor number
| | |
0.965
|
|
Solitary
|
358 (94.0%)
|
153 (93.9%)
| |
|
Multiple
|
23 (6.0%)
|
10 (6.1%)
| |
|
Hepatectomy
| | |
0.297
|
|
Anatomical
|
213 (55.9%)
|
99 (60.7%)
| |
|
Nonanatomical
|
168 (44.1%)
|
64 (39.3%)
| |
|
Hemorrhage, ml
| | |
0.498
|
|
<200
|
133 (34.9%)
|
52 (31.9%)
| |
|
≥ 200
|
248 (65.1%)
|
111 (68.1%)
| |
|
Intraoperative transfusion
| | |
0.606
|
|
Yes
|
30 (7.9%)
|
15 (9.2%)
| |
|
No
|
351 (92.1%)
|
148 (90.8%)
| |
|
Differentiation
| | |
0.927
|
|
poor
|
169 (44.4%)
|
73 (44.8%)
| |
|
Well-moderate
|
212 (55.6%)
|
90 (55.2%)
| |
|
MVI
| | |
0.477
|
|
Present
|
124 (32.5%)
|
48 (29.4%)
| |
|
Absent
|
257 (67.5%)
|
115 (70.6%)
| |
|
Capsule
| | |
0.789
|
|
Incomplete
|
215 (56.4%)
|
94 (57.7%)
| |
|
Complete
|
166 (43.6%)
|
69 (42.3%)
| |
- ASA American Society of Anesthesiologists, BMI Body mass index, AFP α-fetoprotein, ALT Alanine transaminase, AST Aspartate aminotransferase, NLR Neutrophil-to-lymphocyte ratio, PLR Platelet lymphocyte ratio, MVI Microvascular invasion
